NCT03473340 - Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

July 23, 2021

Study Completion Date

August 20, 2021

Conditions

Disorder Related to Lung TransplantationChronic Lung Allograft Dysfunction

Interventions

DRUG

Pirfenidone Capsule

"Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"

DRUG

Placebo Capsule

"Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"

Trial Locations (1)

48109

The University of Michigan, Ann Arbor